CT-based radiogenomics of intrahepatic cholangiocarcinoma

Dig Liver Dis. 2025 Jan;57(1):118-124. doi: 10.1016/j.dld.2024.06.033. Epub 2024 Jul 12.

Abstract

Background: Intrahepatic cholangiocarcinoma (ICC) is an aggressive disease with increasing incidence and its genetic alterations could be the target of systemic therapies.

Aims: To elucidate if radiomics extracted from computed tomography (CT) may non-invasively predict ICC genetic alterations.

Methods: All consecutive patients with a diagnosis of a mass-forming ICC (01/2016-06/2022) were considered. Inclusion criteria were availability of a high-quality contrast-enhanced CT and molecular profiling by NGS or FISH for FGFR2 fusion/rearrangement. The CT scan at diagnosis was considered. Genetic analyses were performed on surgical specimens (resectable patients) or biopsies (unresectable ones). The radiomic features were extracted using the LifeX software. Multivariate predictive models of the commonest genetic alterations were built.

Results: In the 90 enrolled patients (58 NGS/32 FISH, median age 65 years), the most common genetic alterations were FGFR2 (20/90), IDH1 (10/58), and KRAS (9/58). At internal validation, the combined clinical-radiomic models achieved the best performance for the prediction of FGFR2 (AUC = 0.892) and IDH1 status (AUC = 0.819), outperforming the pure clinical and radiomic models. The radiomic model for predicting KRAS mutations achieved an AUC = 0.767 (vs. 0.660 of the clinical model) without further improvements with the addition of clinical features.

Conclusions: CT-based radiomics provides a reliable non-invasive prediction of ICC genetic status with a major impact on therapeutic strategies.

Keywords: Genetics; Precision medicine; Radiomics; Texture analysis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bile Duct Neoplasms* / diagnostic imaging
  • Bile Duct Neoplasms* / genetics
  • Bile Duct Neoplasms* / pathology
  • Cholangiocarcinoma* / diagnostic imaging
  • Cholangiocarcinoma* / genetics
  • Cholangiocarcinoma* / pathology
  • Female
  • Humans
  • In Situ Hybridization, Fluorescence
  • Isocitrate Dehydrogenase* / genetics
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Receptor, Fibroblast Growth Factor, Type 2* / genetics
  • Tomography, X-Ray Computed*

Substances

  • Receptor, Fibroblast Growth Factor, Type 2
  • FGFR2 protein, human
  • KRAS protein, human
  • Isocitrate Dehydrogenase
  • Proto-Oncogene Proteins p21(ras)
  • IDH1 protein, human